FDA approves single-pill regimen HIV med

The FDA clears ViiV Healthcare's Triumeq (abacavir 600 mg, dolutegravir 50 mg, lamivudine 300 mg) for the treatment of HIV-1 infection. The single-pill regimen combines the integrase strand transfer inhibitor dolutegravir with the nucleoside reverse transcriptase inhibitors abacavir and lamivudine.

ViiV Healthcare is an HIV-focused company established in 2009 by GlaxoSmithKline (GSK -1.6%) and Pfizer (PFE +0.5%). Shionogi joined the venture in October 2012.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs